Orgenesis (Orgenesis) Days Payable : 2,131.76 (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Days Payable?

Orgenesis's average Accounts Payable for the three months ended in Mar. 2024 was $11.49 Mil. Orgenesis's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.49 Mil. Hence, Orgenesis's Days Payable for the three months ended in Mar. 2024 was 2,131.76.

The historical rank and industry rank for Orgenesis's Days Payable or its related term are showing as below:

ORGS' s Days Payable Range Over the Past 10 Years
Min: 83.32 Med: 191.37 Max: 658.67
Current: 658.67

During the past 13 years, Orgenesis's highest Days Payable was 658.67. The lowest was 83.32. And the median was 191.37.

ORGS's Days Payable is ranked better than
79.78% of 722 companies
in the Biotechnology industry
Industry Median: 148.145 vs ORGS: 658.67

Orgenesis's Days Payable increased from Mar. 2023 (147.77) to Mar. 2024 (2,131.76). It may suggest that Orgenesis delayed paying its suppliers.

Orgenesis Days Payable Historical Data

The historical data trend for Orgenesis's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Days Payable Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

131.93

83.32

87.73

343.70

321.32

Orgenesis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															147.77	117.82	2,935.10	3,257.68	2,131.76

Competitive Comparison of Orgenesis's Days Payable

For the Biotechnology subindustry, Orgenesis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orgenesis's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Days Payable distribution charts can be found below:

* The bar in red indicates where Orgenesis's Days Payable falls into.

Orgenesis Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Orgenesis's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (4.429	+	6.584)	/	2 )	/	6.255	*	365
=	5.5065					/	6.255	*	365
=	321.32

Orgenesis's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (6.584	+	16.404)	/	2 )	/	0.492	*	365 / 4
=	11.494					/	0.492	*	365 / 4
=	2,131.76

Orgenesis Days Payable Related Terms

Thank you for viewing the detailed overview of Orgenesis's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (Orgenesis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

45O:Germany

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Executives

Elliot Maltz	officer: Chief Financial Officer	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier	10 percent owner	C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik	officer: Chief Development Officer	C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips	director	C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber	officer: Chief Scientific Officer	17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin	director	7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler	director	4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan	officer: CEO	20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles	10 percent owner	AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger	10 percent owner	DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus	10 percent owner	ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret	officer: See Remarks	48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda	director	2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452